Effect of Cytochrome P450 and ABCB1 Polymorphisms on Imatinib Pharmacokinetics After Single-Dose Administration to Healthy Subjects
ConclusionCYP2B6 G516Tand CYP3A4 *20,*22 polymorphisms could influence imatinib plasma concentrations and safety profile, after single-dose administration to healthy subjects. This finding needs to be confirmed before it is implemented in clinical practice in oncological patients under treatment with imatinib.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Genetics | Gleevec | Study | Toxicology